FindTrial
Sign In

Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients With Gastritis

A Multi-Center, Randomized, Parallel, Double-Blind, Phase III Clinical Trial to Compare the Efficacy and Safety of DWC20155/DWC20156 Combination Therapy With DWC20155 or DWC20156 Monotherapy in Patients With Gastritis

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03184415
Enrollment
230
Registered
2017-06-12
Start date
2017-07-03
Completion date
2018-05-17
Last updated
2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis

Brief summary

THe purpose of this study is to evaludate the Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients with Gastritis

Interventions

DRUGDWC20155

tablet

DRUGDWC20156

tablet

DRUGplacebo of DWC20155

tablet

DRUGplacebo of DWC20156

tablet

Sponsors

Daewoong Pharmaceutical Co. LTD.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male of female of at least 19 years old * Patients diagnosed with acute or chronic gastritis by gastroscopy * Patients with one or more erosions found by gastroscopy

Exclusion criteria

* Patients with peptic ulcer and gastroesophageal reflux disease * Patients with previous gastrointestinal surgery * Patients with history of gastrointestinal cancer

Design outcomes

Primary

MeasureTime frame
Improvement rates of stomach erosions by the endoscopyAt 2 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026